Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 2,334

The DOI matches its Crossref record.

Nanoparticle and targeted systems for cancer therapy

Brannon-Peppas, Lisa, Blanchette, James O.·2004·Advanced Drug Delivery Reviews
DOI 10.1016/j.addr.2004.02.014
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.addr.2004.02.014

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 43

  1. Feng, 2003, Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases, Chemical Engineering Science, 58, 4087, 10.1016/S0009-2509(03)00234-3 · DOI · Paper page
  2. Grossfeld, 2002, Thrombospondin-1 expression in patients with pathologic state T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis and tumor progression, Urology, 59, 97, 10.1016/S0090-4295(01)01476-5 · doi:10.1016/s0090-4295(01)01476-5
  3. Jones, 1998, New developments in angiogenesis: a major mechanism for tumor growth and target for therapy, Cancer Journal from Scientific American, 4, 209
  4. Brigger, 2002, Nanoparticles in cancer therapy and diagnosis, Advanced Drug Delivery Reviews, 54, 631, 10.1016/S0169-409X(02)00044-3 · DOI · Paper page
  5. Gaur, 2000, Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system, International Journal of Pharmaceutics, 202, 1, 10.1016/S0378-5173(99)00447-0 · DOI · Paper page
  6. Storm, 1995, Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system, Advanced Drug Delivery Reviews, 17, 31, 10.1016/0169-409X(95)00039-A · DOI · Paper page
  7. Jain, 1999, Transport of molecules, particles and cells in solid tumors, Annual Review of Biomedical Engineering, 1, 241, 10.1146/annurev.bioeng.1.1.241 · DOI · Paper page
  8. Sledge, 2003, Exploiting the hallmarks of cancer: the future conquest of breast cancer, European Journal of Cancer, 39, 1668, 10.1016/S0959-8049(03)00273-9 · DOI
  9. Teicher, 2000, Molecular targets and cancer therapeutics: discovery, development and clinical validation, Drug Resistance Updates, 3, 67, 10.1054/drup.2000.0123 · doi:10.1054/drup.2000.0123
  10. Chari, 1998, Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy, Advanced Drug Delivery Reviews, 31, 89, 10.1016/S0169-409X(97)00095-1 · DOI · Paper page
  11. Suzawa, 2002, Enhanced tumor cell selectivity of adriamycin-monoclonal antobody conjugate via a poly(ethylene-glycol)-based cleavable linker, Journal of Controlled Release, 79, 229, 10.1016/S0168-3659(01)00554-5 · DOI
  12. Kohler, 1975, Continuous cultures of fuse cells secreting antibody of predefined specificity, Nature, 75, 381
  13. Abou-Jawde, 2003, An overview of targeted treatments in cancer, Clinical Therapeutics, 25, 2121, 10.1016/S0149-2918(03)80209-6 · DOI
  14. Glennie, 2003, Renaissance of cancer therapeutic antibodies, Drug Discovery Today, 8, 503, 10.1016/S1359-6446(03)02714-4 · DOI
  15. Hobson, 1984, Endothelial proliferation in tumors and normal tissues: continuous labeling studies, British Journal of Cancer, 49, 405, 10.1038/bjc.1984.66 · DOI · Paper page
  16. Fox, 1993, Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer, Cancer Research, 53, 4161
  17. Sepp, 1997, Endothelial cells and angiogenesis, Experimental Dermatology, 6, 272, 10.1111/j.1600-0625.1997.tb00172.x · doi:10.1111/j.1600-0625.1997.tb00172.x
  18. Ingber, 1990, Fibronectin controls capillary endothelial cells growth by modulating cell shape, Proceedings of the National Academy of Sciences, 87, 3579, 10.1073/pnas.87.9.3579 · DOI · Paper page
  19. Eatock, 2000, Tumor vasculature as a target for anticancer therapy, Cancer Treatment Reviews, 26, 191, 10.1053/ctrv.1999.0158 · DOI
  20. Chen, 2001, Targeting tumor angiogenesis with gene therapy, Molecular Genetics and Metabolism, 74, 120, 10.1006/mgme.2001.3223 · DOI
  21. Reynolds, 2003, Nanoparticle-mediated gene delivery to tumor vasculature, Trends in Molecular Medicine, 9, 2, 10.1016/S1471-4914(02)00004-7 · DOI
  22. Folkman, 1989, Successful treatment of an angiogenic disease, New England Journal of Medicine, 320, 1211, 10.1056/NEJM198905043201811 · DOI · Paper page
  23. Hood, 2002, Tumor regression by targeted gene delivery to the neovasculature, Science, 296, 2404, 10.1126/science.1070200 · DOI · Paper page
  24. Singla, 2002, Paclitaxel and its formulations, International Journal of Pharmaceutics, 235, 179, 10.1016/S0378-5173(01)00986-3 · DOI · Paper page
  25. Wang, 1996, Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of novel anticancer agent, taxol, Chemical and Pharmaceutical Bulletin, 44, 1935, 10.1248/cpb.44.1935 · DOI
  26. Si-Shen, 2001, Effect of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymer, Journal of Controlled Release, 71, 53, 10.1016/S0168-3659(00)00364-3 · DOI · Paper page
  27. Fonseca, 2002, Paclitaxel-loaded PLGA nanoparticles: preparation, phsiochemical characterization and in vitro anti-tumoral activity, Journal of Controlled Release, 83, 273, 10.1016/S0168-3659(02)00212-2 · DOI · Paper page
  28. Mu, 2003, A novel controlled release formulation for the anticancer drug paclitaxel (taxol): PLGA nanoparticles containing vitamin E TPGS, Journal of Controlled Release, 86, 33, 10.1016/S0168-3659(02)00320-6 · DOI · Paper page
  29. Yoo, 2000, In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates, Polymer Preparation, 41, 992
  30. Mitra, 2001, Tumour targeted delivery of encapsulated dextran–doxorubicin conjugate using chitosan nanoparticles as carrier, Journal of Controlled Release, 74, 317, 10.1016/S0168-3659(01)00342-X · DOI · Paper page
  31. Shikata, 2002, In vitro cellular accumulation of gadolinium incorporated into chitosan nanoparticles designed for neutron-capture therapy of cancer, European Journal of Pharmaceutics and Biopharmaceutics, 53, 57, 10.1016/S0939-6411(01)00198-9 · DOI
  32. Bhadra, 2003, A PEGylated dendritic nanoparticulate carrier of fluorouracil, International Journal of Pharmaceutics, 257, 111, 10.1016/S0378-5173(03)00132-7 · DOI · Paper page
  33. Williams, 2003, Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors, Journal of Controlled Release, 91, 167, 10.1016/S0168-3659(03)00241-4 · doi:10.1016/s0168-3659(03)00241-4
  34. Kircheis, 1997, Coupling of cell-binding ligands to polyethylenimine for targeted gene transfer, Gene Therapy, 4, 409, 10.1038/sj.gt.3300418 · DOI · Paper page
  35. Blessing, 2001, Different strategies for formulation of PEGylated EGF-conjugated PEI/DNA complexes for targeted gene delivery, Bioconjugate Chemistry, 12, 529, 10.1021/bc0001488 · DOI · Paper page
  36. Ogris, 2001, DNA/polyethylenimine transfection particles: influence of ligands, polymer size, and PEGylation on internalization and gene expression, AAPS PharmSciTech, 3
  37. Ogris, 2003, Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethyleneimine/DNA complexes, Journal of Controlled Release, 91, 173, 10.1016/S0168-3659(03)00230-X · DOI · Paper page
  38. Becerril, 1999, Toward selection of internalizing antibodies from phage libraries, Biochemical and Biophysical Research Communications, 255, 386, 10.1006/bbrc.1999.0177 · DOI
  39. Nielsen, 2002, Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antobody selected for cellular endocytosis, Biochimica et Biophysica Acta, 1591, 109, 10.1016/S0167-4889(02)00256-2 · DOI · Paper page
  40. Kim, 2003, Development of polymeric nanoparticulate drug delivery systems: evaluation of nanoparticles based on biotinylated poly(ethylene glycvol) with sugar moiety, International Journal of Pharmaceutics, 257, 195, 10.1016/S0378-5173(03)00128-5 · DOI
  41. Lu, 2003, Immunotherapy of folate receptor-expressing tumors: review of recent advances and future prospects, Journal of Controlled Release, 91, 18, 10.1016/S0168-3659(03)00215-3 · DOI · Paper page
  42. Rodolfo, 1998, IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine associated with the eradication of experimental metastases, Cancer Research, 58, 5812
  43. Dagar, 2003, VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies, Journal of Controlled Release, 91, 123, 10.1016/S0168-3659(03)00242-6 · DOI

Cited by

See all 2,334

Metadata

Authors
Brannon-Peppas, L., & Blanchette, J. O.
Venue
Advanced Drug Delivery Reviews
Publisher
Elsevier BV
Published
2004-09
Volume
56
Issue
11
Pages
1649-1659
ISSN
0169-409X (ISSN-L)
DOI
10.1016/j.addr.2004.02.014
OpenAlex
W2095248480
Cited by
2,334
References
0
FWCI
4.18
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nanoparticle and targeted systems for cancer therapy. https://app.cochat.ai/papers/10.1016/j.addr.2004.02.014
The paper
Brannon-Peppas, L., & Blanchette, J. O. (2004). Nanoparticle and targeted systems for cancer therapy. Advanced Drug Delivery Reviews. https://doi.org/10.1016/j.addr.2004.02.014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.